Register
Login:
Share:
Email Facebook Twitter




Quick Poll
QUICK POLL >
Would you use a professional standard news service? (Giving you breaking news sooner)




SAR Share Chat - RSS Feed

Sareum Share Chat (SAR)



Share Price: 0.325Bid: 0.30Ask: 0.35Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.05Spread as %: 16.67%Open: 0.325High: 0.325Low: 0.285Yesterday’s Close: 0.325


Share Discussion for Sareum (SAR)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


50sBoy
Posts: 341
Off Topic
Opinion:No Opinion
Price:0.63
sadoldgit
4 Jun '14
Thanks for taking the time to reply yesterday, i see what you mean now with the spread., appreciated.
Good luck to you and your investments also
 
ozzie43
Posts: 1,044
Observation
Opinion:No Opinion
Price:0.63
Don't forget TYK2....
4 Jun '14
Just be re-reading earlier RNS from Feb this year. This bit got me thinking a bit:

Auto-immune diseases and inflammatory disorders - TYK2+JAK1

Our auto-immune diseases programme is conducted in collaboration with SRI International (SRI), following the agreement announced in April 2013. The disease biology expertise at SRI has focused on disease models that demonstrate how programme compounds are able to block TYK2 dependent signalling.

Steady progress has been made since our last update. In a psoriasis disease model established at SRI, oral administration of the lead molecules leads to a significant reduction in the scaling and redness associated with the disease. Furthermore, the levels of many of the cytokines (signalling molecules) and other proteins thought to be responsible for the symptoms of psoriasis, were shown to be reduced by the addition of programme compounds. In a "rapid efficacy" model also established at SRI, levels of interferon-gamma, a cytokine involved in a number of autoimmune and inflammatory diseases, were shown to be reduced following oral administration of our lead compounds. This model allows us to rapidly screen compounds for biological activity before progressing them into more resource-intensive disease models.

These studies have also indicated that certain of our lead compounds are producing this effect via a combination of TYK2 and JAK1 inhibition. JAK1, like TYK2, is another member of the JAK family of kinases, and is essential for signalling by a number of cytokines also involved in psoriasis, as well as inflammatory bowel disease and rheumatoid arthritis. Our compounds will be tested on models of these diseases in due course. Research into JAK1 has been the subject of considerable scientific interest of late and has resulted in several valuable clinical stage licensing deals.

We are planning to publish the results of our studies in scientific literature and present them at conferences during 2014. An additional patent application protecting programme compounds was published in September 2013.
Stach
Posts: 5,139
Observation
Opinion:No Opinion
Price:0.63
Hello to All,who held for so long!
4 Jun '14
The-Oracle's remark not to be sniffed at- Tim did it before! On a brighter note,the chinese would only need six months to assess if FLT-3 obtained via SAR,has worked in their leukaemic patients or not.They could easily also have been simultaneously testing it against the competitor FLT-3 Inhibitor such as one obtained from Cephalon(USA).I am not sure about their Regulations but convinced that they are far more flexible than those in Europe and the USA.Stach
The-Oracle
Posts: 330
Off Topic
Opinion:No Opinion
Price:0.63
lol
4 Jun '14
You all reason as if we haven't been here before. Sareum could rise to 1.50 today and Tim will show his face and say no reason for rise. And this is Sar might I remind people fluctuations are the norm. Until hardcore rns shows up.
BOOKMAN
Posts: 1,446
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.63
nothing happens
4 Jun '14
for no reason......sareum will discover it full power NOW
kazimira
Posts: 133
Off Topic
Opinion:No Opinion
Price:0.60
Enter stage left
4 Jun '14
News, news! my kingdom for a nugget of hard news!
maytheforcework
Posts: 3,770
Off Topic
Opinion:No Opinion
Price:0.60
China
4 Jun '14
Probably already testing on humans, they don't need any approvals from anyone they just do it. Obviously if results are promising which on mice was 100% successful we can expect some positive feed back and then as leaks occur we will see share price spikes. Just my thoughts. Happy to wait.
BOOKMAN
Posts: 1,446
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.60
SAReum
4 Jun '14
THE MORE SAREUM DOES AND KEEPS BUSY WITH MEETINGS, CONTACTS, AND NETWORKING ....the better we can dance with the dreams we all want here ..taking action and guessing wrong GUESSES for spikes in share price is still doing good boys so if anyone has any ideas ..please share with the board its all little steps and everything matters.goodluck
stockraider
Posts: 1,519
Off Topic
Opinion:No Opinion
Price:0.60
View Thread (2)
RE: not just china
4 Jun '14
thats old news from here
http://www.businessweekly.co.uk/biomedtech-/16224-cambridge-china-cancer-programme-advanced

let's face it.. we don't know yet why SAR is up but defo something brewing
Hopkirk
Posts: 1,238
Off Topic
Opinion:No Opinion
Price:0.60
Bookman
4 Jun '14
I would expect news from HMU soon or certainly within the next 2 months (to say if they are applying for trials on Aurora FLT3) but we may not hear until approval is granted.

But the only milestone payment we may get is when marketing approval is granted in about 5 years.

But keep guessing. ;)





Sign up for Live Prices


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.